Evidence map›Paper›PMID 27073573›Full record

ArticleOncology letters2016

Metformin use and young age lung cancer: A case series report.

B O Deng, Y I Wang, Dong Xie, Shawn M Stoddard, Ping Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

B O DengDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA; Department of Thoracic Surgery, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing 400042, P.R. China.
Y I WangDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA; Division of Preventive Medicine, School of Environmental Science and Public Health, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China.
Dong XieDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA; Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, P.R. China.
Shawn M StoddardDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Ping YangDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.

Funding

ALPHA 1 AD CARRIERS AND LUNG CANCER RISKR01CA080127 · NCI · MAYO CLINIC ROCHESTER · PI YANG, PING · 2000 to 2009
$4.4M
Genetic Determinants of Lung Cancer SurvivalR01CA084354 · NCI · MAYO CLINIC ROCHESTER · PI YANG, PING · 2001 to 2012
$4.0M
DEVELOPMENT OF LUNG CANCER EPIDEMIOLOGY RESEARCHR03CA077118 · NCI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI YANG, PING · 1997 to 1998
–
NCI NIH HHS R01 CA080127NCI NIH HHS R01 CA084354NCI NIH HHS R03 CA077118
6 · The paper itself

Abstract

Metformin, a widely-prescribed antihyperglycemic drug for the treatment of diabetes mellitus type 2 (DM-II), has been demonstrated to be antineoplastic

Indexed as

lung cancermetforminneuroendocrine tumors

Identifiers

PMID27073573
PMCPMC4812209

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.